kabutan

Pharma Foods International Co., Ltd.(2929) Summary

2929
TSE Prime
Pharma Foods International Co., Ltd.
660
JPY
-12
(-1.79%)
Dec 15, 3:30 pm JST
4.25
USD
Dec 15, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
19.1
PBR
2.05
Yield
3.79%
Margin Trading Ratio
2.27
Stock Price
Dec 15, 2025
Opening Dec 15, 9:00 am
669 JPY 4.29 USD
Previous Close Dec 12
672 JPY 4.31 USD
High Dec 15, 9:30 am
686 JPY 4.39 USD
Low Dec 15, 2:16 pm
657 JPY 4.23 USD
Volume
408,500
Trading Value
0.27B JPY 1.76M USD
VWAP
667.93 JPY 4.31 USD
Minimum Trading Value
66,000 JPY 425 USD
Market Cap
0.02T JPY 0.12B USD
Number of Trades
662
Liquidity & Number of Trades
As of Dec 15, 2025
Liquidity
Slightly High
1-Year Average
435
1-Year High Sep 11, 2025
4,808
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 143,800 788,900 5.49
Nov 28, 2025 123,100 753,600 6.12
Nov 21, 2025 122,700 727,100 5.93
Nov 14, 2025 132,000 734,700 5.57
Nov 7, 2025 128,800 834,000 6.48
Company Profile
Pharma Foods International Co., Ltd. primarily sells functional food ingredients such as GABA and folic acid egg supplements. The company is also involved in the development of antibody-based pharmaceuticals.
Sector
Foods
Pharma Foods International Co., Ltd. engages in the research, development, and manufacturing of functional ingredients, health foods, and pharmaceuticals. The company operates a B2B business, supplying materials to food and pharmaceutical manufacturers as well as distributors. They offer ingredients such as Pharma GABA, which provides stress relief and blood pressure improvement functions. Additionally, the company develops and sells its own brand products both domestically and internationally. In their B2C business, Pharma Foods International directly sells supplements, quasi-drugs, and cosmetics containing their proprietary functional ingredients to consumers through mail order. The Biomedical division conducts drug discovery research and development targeting intractable diseases such as autoimmune disorders and fibrosis, while also providing contracted services like proteome analysis. Furthermore, the company has expanded into venture capital and investment businesses.